Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 2
1978 2
1979 1
1980 3
1981 4
1982 9
1983 7
1984 18
1985 35
1986 32
1987 38
1988 37
1989 54
1990 60
1991 52
1992 47
1993 60
1994 80
1995 65
1996 86
1997 79
1998 89
1999 101
2000 102
2001 92
2002 102
2003 108
2004 94
2005 105
2006 163
2007 131
2008 132
2009 157
2010 171
2011 178
2012 227
2013 204
2014 227
2015 243
2016 213
2017 222
2018 235
2019 233
2020 257
2021 245
2022 253
2023 221
2024 67

Text availability

Article attribute

Article type

Publication date

Search Results

4,824 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for cisplatin accord
Your search for cisplatino-accord retrieved no results
Cisplatin in Ovarian Cancer Treatment-Known Limitations in Therapy Force New Solutions.
Zoń A, Bednarek I. Zoń A, et al. Int J Mol Sci. 2023 Apr 20;24(8):7585. doi: 10.3390/ijms24087585. Int J Mol Sci. 2023. PMID: 37108749 Free PMC article. Review.
Cisplatin is one of the most commonly used anticancer drugs worldwide. ...In addition, our goal was to highlight a number of therapeutic strategies to increase the effectiveness of cisplatin in the treatment of ovarian cancer, as well as to identify methods to elimi …
Cisplatin is one of the most commonly used anticancer drugs worldwide. ...In addition, our goal was to highlight a number of therapeu …
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Galsky MD, Guan X, Rishipathak D, Rapaport AS, Shehata HM, Banchereau R, Yuen K, Varfolomeev E, Hu R, Han CJ, Li H, Liang Y, Vucic D, Wang L, Zhu J, Yu H, Herbst RH, Hajaj E, Kiner E, Bamias A, De Santis M, Davis ID, Arranz JÁ, Kikuchi E, Bernhard S, Williams P, Lee C, Mellman I, Sanjabi S, Johnston R, Black PC, Grande E, Mariathasan S. Galsky MD, et al. Cell Rep Med. 2024 Feb 20;5(2):101393. doi: 10.1016/j.xcrm.2024.101393. Epub 2024 Jan 26. Cell Rep Med. 2024. PMID: 38280376 Free PMC article. Clinical Trial.
In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease control in a subset of patients. ...These results underscore the key role of immune modulation in cisplatin's efficacy in mUC and highlight the importance of specific …
In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease control in a subset of patients. ...Thes …
Cisplatin for testicular germ cell tumors: a rapid review.
Hu Z, Yu J, Gui G, Chen Y, Huang R, Jiang L, Kwong JSW, Li Y, Zhang L. Hu Z, et al. J Evid Based Med. 2016 Aug;9(3):144-151. doi: 10.1111/jebm.12210. J Evid Based Med. 2016. PMID: 27376482 Review.
The Union for International Cancer Control recommended cisplatin to the 19(th) WHO EML for TGCT. To evaluate the effectiveness, safety and cost of cisplatin for TGCT according to the requirements of WHO EML Expert Committee, and to provide the evidence whethe …
The Union for International Cancer Control recommended cisplatin to the 19(th) WHO EML for TGCT. To evaluate the effectiveness, safet …
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Zubel A, Zanna C, Brienza S, Crompton P, Rouits E, Gollmer K, Szyldergemajn S, Bourhis J. Sun XS, et al. Lancet Oncol. 2020 Sep;21(9):1173-1187. doi: 10.1016/S1470-2045(20)30327-2. Epub 2020 Aug 3. Lancet Oncol. 2020. PMID: 32758455 Clinical Trial.
BACKGROUND: Debio 1143 is an orally available antagonist of inhibitor of apoptosis proteins with the potential to enhance the antitumour activity of cisplatin and radiotherapy. The radiosensitising effect of Debio 1143 is mediated through caspase activation and TNF, IFNgam …
BACKGROUND: Debio 1143 is an orally available antagonist of inhibitor of apoptosis proteins with the potential to enhance the antitumour act …
Long-term toxicity of cisplatin in germ-cell tumor survivors.
Chovanec M, Abu Zaid M, Hanna N, El-Kouri N, Einhorn LH, Albany C. Chovanec M, et al. Ann Oncol. 2017 Nov 1;28(11):2670-2679. doi: 10.1093/annonc/mdx360. Ann Oncol. 2017. PMID: 29045502 Free PMC article. Review.
The cumulative dose of cisplatin and circulating platinum were reported as risk factors. Several single-nucleotide polymorphisms identified patients susceptible to cisplatin compared with wild-type individuals. CONCLUSIONS: GCT survivors cured with cisplatin- …
The cumulative dose of cisplatin and circulating platinum were reported as risk factors. Several single-nucleotide polymorphisms iden …
État des lieux des pratiques de prise en charge des cancers des voies biliaires en France : résultats de l'enquête nationale ACABi.
Delaye M, Assenat E, Boleslawski E, Camus M, Edeline J, Henriques J, Herrero A, Lièvre A, Malka D, Turpin A, Vernerey D, Neuzillet C. Delaye M, et al. Bull Cancer. 2022 Nov;109(11S):11S3-11S10. doi: 10.1016/S0007-4551(22)00463-5. Bull Cancer. 2022. PMID: 36535761 Free article. Review. French.
METHODS: A questionnaire was developed by a multidisciplinary team and distributed (June-July 2021) by the French digestive oncology societies. The data were analyzed according to the type of practice center (group A: university hospital or cancer comprehensive center, gro …
METHODS: A questionnaire was developed by a multidisciplinary team and distributed (June-July 2021) by the French digestive oncology societi …
Disparities in Cisplatin-Induced Cytotoxicity-A Meta-Analysis of Selected Cancer Cell Lines.
Ćwiklińska-Jurkowska M, Wiese-Szadkowska M, Janciauskiene S, Paprocka R. Ćwiklińska-Jurkowska M, et al. Molecules. 2023 Jul 30;28(15):5761. doi: 10.3390/molecules28155761. Molecules. 2023. PMID: 37570731 Free PMC article. Review.
Cisplatin is a classic anticancer drug widely used as a reference drug to test new metal complex drug candidates. ...According to the random effect model, the 95% confidence intervals for IC(50) were extremely wide. ...
Cisplatin is a classic anticancer drug widely used as a reference drug to test new metal complex drug candidates. ...According …
Cisplatin-induced nephrotoxicity in childhood cancer: comparison between two countries.
Zazuli Z, Op 't Hoog CJP, Vijverberg SJH, Masereeuw R, Rassekh SR, Medeiros M, Rivas-Ruiz R, Maitland-van der Zee AH, Carleton BC. Zazuli Z, et al. Pediatr Nephrol. 2023 Feb;38(2):593-604. doi: 10.1007/s00467-022-05632-z. Epub 2022 Jun 24. Pediatr Nephrol. 2023. PMID: 35748941
BACKGROUND: Various definitions used to describe cisplatin nephrotoxicity potentially lead to differences in determination of risk factors. This study evaluated incidence of kidney injury according to commonly used and alternative definitions in two cohorts of child …
BACKGROUND: Various definitions used to describe cisplatin nephrotoxicity potentially lead to differences in determination of risk fa …
MFAP2 enhances cisplatin resistance in gastric cancer cells by regulating autophagy.
Li M, Zhang HY, Zhang RG. Li M, et al. PeerJ. 2023 Jun 7;11:e15441. doi: 10.7717/peerj.15441. eCollection 2023. PeerJ. 2023. PMID: 37304872 Free PMC article.
BACKGROUND: Cisplatin (CDDP) is of importance in cancer treatment and widely used in advanced gastric cancer (GC). ...Then, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis and survival analysis were conducted. Furthermore, accordin …
BACKGROUND: Cisplatin (CDDP) is of importance in cancer treatment and widely used in advanced gastric cancer (GC). ...Then, Gene Onto …
Cisplatin resistance-related multi-omics differences and the establishment of machine learning models.
Sui Q, Chen Z, Hu Z, Huang Y, Liang J, Bi G, Bian Y, Zhao M, Zhan C, Lin Z, Wang Q, Tan L. Sui Q, et al. J Transl Med. 2022 Apr 11;20(1):171. doi: 10.1186/s12967-022-03372-0. J Transl Med. 2022. PMID: 35410350 Free PMC article.
RESULTS: 661 cell lines were divided into three groups according to the IC50 value of cisplatin, and the top 1/3 (220) with a small IC50 value were defined as the sensitive group while the last 1/3 (220) were enrolled in the insensitive group. TP53 was the most comm …
RESULTS: 661 cell lines were divided into three groups according to the IC50 value of cisplatin, and the top 1/3 (220) with a …
4,824 results